The University of Iowa is a NSF I-Corps site managed by UIVentures and JPEC. Our program offers workshops to introduce faculty, staff, (and now) graduate students and postdocs to research commercialization. Their product or service, is called their intellectual property or IP, and is typically based on research discoveries or inventions achieved in a UI lab.
Voxello, the producer of the noddle, a medical device that helps impaired patients communicate with nurses and caregivers, has received FDA clearance for the trademarked device, and recently closed a Series A funding round of more than $800,000.
Immortagen Inc., based in Iowa City, a cancer diagnostics company that develops cloud-based precision medicine using a proprietary software platform, received a $100,000 loan from the Demonstration Fund for proof of concept work and key personnel.
Market: Cancer Genome Sequencing
Immortagen seeks to personalize cancer treatment through private tumor banking, full spectrum genetic profiling, revolutionary Clinical Decision Support algorithms, and advanced mouse models for drug research and development.
The UIRF has prepared low impact Standstill and License Agreements for UI ventures. These agreements contain standardized terms, dramatically reducing or even eliminating time consuming negotiations between the startup and the UIRF.
The US Federal Trade Commission (FTC) has published an online tool designed to help developers of mobile medical and telehealth apps determine which laws and regulations pertain to their products.
Designed with input from the Food and Drug Administration and other agencies, the Mobile Health Apps Interactive Tool presents a series of questions for developers to see whether they must comply with one or more of the following US laws:
Health Insurance Portability and Accountability Act (HIPAA), enforced by the US Department of Health & Human Services
